We Are Proud to Announce the DIA 2018 Honorary Chairs!
Julie Louise Gerberding, MD, MPh, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health, Merck & Co., Inc.
Tatsuya Kondo, PhD, MD, Chief Executive, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Biographies
Julie Louise Gerberding, MD, MPh
Dr. Julie Gerberding is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health at Merck & Co., Inc., where she also has responsibility for the Merck for Mothers program and the Merck Foundation. As Chief Patient Officer, Dr. Gerberding leads efforts to engage with patients and patient organizations to bring their perspectives into Merck and MSD to help inform company decisions and represents Merck globally on patient-related matters. In addition, she is building new initiatives designed to accelerate Merck’s ability to contribute to improved population health, a measure increasingly valued by consumers, health organizations, and communities.
As a world-renowned infectious disease and public health expert, Dr. Gerberding is a leader well-versed in and passionate about acting with purpose and urgency to meet patient needs. She joined Merck in January 2010 as president of Merck Vaccines and, during her leadership of that business, helped make the company’s vaccines increasingly more available and affordable to people in emerging markets and some of the most resource-limited countries in the world.
Dr. Gerberding currently serves on the Boards of Cerner Corporation, CWRU, MSD Wellcome Trust Hilleman Laboratories, and the BIO Executive Committee. Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. She was named to Forbes Magazine's 100 Most Powerful Women in the World in 2005 through 2008 and to TIME Magazine's 100 Most Influential People in the World in 2004.
“This is THE place to be if you’re interested in a broad range of issues that relate to patient engagement, pharmaceutical clinical trial development, and a whole host of related issues of interest to both patients and industry, as well as payers and providers. It’s a wonderful network of the key opinion leaders–the smartest people and I think the most passionate people in this sector–and it’s just an honor to be part of the overall program and to serve in this role.”
Listen in to DIA's exclusive podcast with Dr. Gerberding as she spotlights gender parity efforts of Merck Women’s Network and explores “legitimization of a number of different dimensions of patient engagement” in clinical research and healthcare product development.
Tatsuya Kondo, PhD, MD
Dr. Tatsuya Kondo is Chief Executive of Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. He has been in this position since 2008. He is responsible for all the operations of PMDA that related to adverse health effects of drugs, drug/medical devices reviews, and post-marketing safety measures and more. He is also a major participant in the International Coalition of Medicines Regulatory Authorities (ICMRA), comprised of top of the Drug Regulatory Agencies.
Before taking the current position, he spent most of his career as a neurosurgeon after he graduated from the Medical Department of the University of Tokyo in 1968. He worked at various medical institutions, including the First National Hospital and Faculty of Medicine at the University of Tokyo.
Currently, he is also serving as the Advisor on Health and Medical Strategy for Cabinet Secretariat of Japanese Government, and as the Vice President of Medical Excellence JAPAN, a general incorporated association.